Cargando…
Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care?
Helicobacter pylori (Hp) management has undoubtedly resulted in a notable economic burden on healthcare systems globally, including Greece. Its cost has never been estimated so far, especially during the recent 10-year unprecedented financial crisis. Direct medical and procedural costs for one attem...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142601/ https://www.ncbi.nlm.nih.gov/pubmed/32197498 http://dx.doi.org/10.3390/medicina56030133 |
_version_ | 1783519419857633280 |
---|---|
author | Liatsos, Christos Papaefthymiou, Apostolis Kyriakos, Nikolaos Giakoumis, Marios Kountouras, Jannis Galanopoulos, Michail Apostolopoulos, Periklis Georgopoulos, Sotirios D. Mavrogiannis, Christos Exadaktylos, Aristomenis K. Srivastava, David Shiva Rokkas, Theodore Doulberis, Michael |
author_facet | Liatsos, Christos Papaefthymiou, Apostolis Kyriakos, Nikolaos Giakoumis, Marios Kountouras, Jannis Galanopoulos, Michail Apostolopoulos, Periklis Georgopoulos, Sotirios D. Mavrogiannis, Christos Exadaktylos, Aristomenis K. Srivastava, David Shiva Rokkas, Theodore Doulberis, Michael |
author_sort | Liatsos, Christos |
collection | PubMed |
description | Helicobacter pylori (Hp) management has undoubtedly resulted in a notable economic burden on healthcare systems globally, including Greece. Its cost has never been estimated so far, especially during the recent 10-year unprecedented financial crisis. Direct medical and procedural costs for one attempt “outpatient” Hp eradication treatment were estimated as the following: (I) first-line regimens: 10 and 14 days standard triple, 10 and 14 days sequential, 10 and 14 days concomitant non-bismuth quadruple, 14 days hybrid, (II) second-line salvage regimens: 10 and 14 days levofloxacin-containing triple regimens. Treatment costs using prototypes and/or generic drugs were calculated. Drug prices were collected and confirmed from two official online medical databases including all medicines approved by the Greek National Organization for Medicines. Regimens based on generics were more affordable than prototypes and those including pantoprazole yielded the lowest prices (mean: 27.84 €). Paradoxically, 10-day concomitant and 14-day hybrid regimens (currently providing good (90–94%) first-line eradication rates in Greece) cost the same (mean: 34.76 €). The expenditures for Hp eradication treatment regimens were estimated thoroughly for the first time in Greece. These data should be taken into account by Public Health policymakers both in Greece and the European Union, aiming for a better and less expensive therapeutic approach. |
format | Online Article Text |
id | pubmed-7142601 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71426012020-04-15 Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care? Liatsos, Christos Papaefthymiou, Apostolis Kyriakos, Nikolaos Giakoumis, Marios Kountouras, Jannis Galanopoulos, Michail Apostolopoulos, Periklis Georgopoulos, Sotirios D. Mavrogiannis, Christos Exadaktylos, Aristomenis K. Srivastava, David Shiva Rokkas, Theodore Doulberis, Michael Medicina (Kaunas) Article Helicobacter pylori (Hp) management has undoubtedly resulted in a notable economic burden on healthcare systems globally, including Greece. Its cost has never been estimated so far, especially during the recent 10-year unprecedented financial crisis. Direct medical and procedural costs for one attempt “outpatient” Hp eradication treatment were estimated as the following: (I) first-line regimens: 10 and 14 days standard triple, 10 and 14 days sequential, 10 and 14 days concomitant non-bismuth quadruple, 14 days hybrid, (II) second-line salvage regimens: 10 and 14 days levofloxacin-containing triple regimens. Treatment costs using prototypes and/or generic drugs were calculated. Drug prices were collected and confirmed from two official online medical databases including all medicines approved by the Greek National Organization for Medicines. Regimens based on generics were more affordable than prototypes and those including pantoprazole yielded the lowest prices (mean: 27.84 €). Paradoxically, 10-day concomitant and 14-day hybrid regimens (currently providing good (90–94%) first-line eradication rates in Greece) cost the same (mean: 34.76 €). The expenditures for Hp eradication treatment regimens were estimated thoroughly for the first time in Greece. These data should be taken into account by Public Health policymakers both in Greece and the European Union, aiming for a better and less expensive therapeutic approach. MDPI 2020-03-18 /pmc/articles/PMC7142601/ /pubmed/32197498 http://dx.doi.org/10.3390/medicina56030133 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Liatsos, Christos Papaefthymiou, Apostolis Kyriakos, Nikolaos Giakoumis, Marios Kountouras, Jannis Galanopoulos, Michail Apostolopoulos, Periklis Georgopoulos, Sotirios D. Mavrogiannis, Christos Exadaktylos, Aristomenis K. Srivastava, David Shiva Rokkas, Theodore Doulberis, Michael Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care? |
title | Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care? |
title_full | Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care? |
title_fullStr | Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care? |
title_full_unstemmed | Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care? |
title_short | Evaluation of the Direct Economic Cost per Eradication Treatment Regimen against Helicobacter pylori Infection in Greece: Do National Health Policy-Makers Need to Care? |
title_sort | evaluation of the direct economic cost per eradication treatment regimen against helicobacter pylori infection in greece: do national health policy-makers need to care? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142601/ https://www.ncbi.nlm.nih.gov/pubmed/32197498 http://dx.doi.org/10.3390/medicina56030133 |
work_keys_str_mv | AT liatsoschristos evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT papaefthymiouapostolis evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT kyriakosnikolaos evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT giakoumismarios evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT kountourasjannis evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT galanopoulosmichail evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT apostolopoulosperiklis evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT georgopoulossotiriosd evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT mavrogiannischristos evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT exadaktylosaristomenisk evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT srivastavadavidshiva evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT rokkastheodore evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare AT doulberismichael evaluationofthedirecteconomiccostpereradicationtreatmentregimenagainsthelicobacterpyloriinfectioningreecedonationalhealthpolicymakersneedtocare |